126 related articles for article (PubMed ID: 16863588)
21. Comparison of seven staging systems in cirrhotic patients with hepatocellular carcinoma in a cohort of patients who underwent radiofrequency ablation with complete response.
Guglielmi A; Ruzzenente A; Pachera S; Valdegamberi A; Sandri M; D'Onofrio M; Iacono C
Am J Gastroenterol; 2008 Mar; 103(3):597-604. PubMed ID: 17970836
[TBL] [Abstract][Full Text] [Related]
22. Treatment of hepatocellular carcinoma with long acting somatostatin analogues.
Samonakis DN; Moschandreas J; Arnaoutis T; Skordilis P; Leontidis C; Vafiades I; Kouroumalis E
Oncol Rep; 2002; 9(4):903-7. PubMed ID: 12066229
[TBL] [Abstract][Full Text] [Related]
23. Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score.
Kudo M; Chung H; Haji S; Osaki Y; Oka H; Seki T; Kasugai H; Sasaki Y; Matsunaga T
Hepatology; 2004 Dec; 40(6):1396-405. PubMed ID: 15565571
[TBL] [Abstract][Full Text] [Related]
24. Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial.
Pinter M; Wichlas M; Schmid K; Plank C; Müller C; Wrba F; Peck-Radosavljevic M
Eur J Gastroenterol Hepatol; 2008 Oct; 20(10):1012-9. PubMed ID: 18787470
[TBL] [Abstract][Full Text] [Related]
25. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method--analysis of 2010 Taiwanese patients.
Chen CH; Hu FC; Huang GT; Lee PH; Tsang YM; Cheng AL; Chen DS; Wang JD; Sheu JC
Eur J Cancer; 2009 Jun; 45(9):1630-9. PubMed ID: 19157858
[TBL] [Abstract][Full Text] [Related]
26. Phase III randomized controlled trial comparing the survival of patients with unresectable hepatocellular carcinoma treated with nolatrexed or doxorubicin.
Gish RG; Porta C; Lazar L; Ruff P; Feld R; Croitoru A; Feun L; Jeziorski K; Leighton J; Gallo J; Kennealey GT
J Clin Oncol; 2007 Jul; 25(21):3069-75. PubMed ID: 17634485
[TBL] [Abstract][Full Text] [Related]
27. [Liver transplantation for the treatment of hepatocellular carcinoma].
Chen XG; Zhu XD; Li W; Liu Y; Zou WL; Niu YJ; Wu FD; Guan ZJ; Yue Y
Zhonghua Zhong Liu Za Zhi; 2006 Aug; 28(8):628-31. PubMed ID: 17236562
[TBL] [Abstract][Full Text] [Related]
28. Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.
Barbare JC; Bouché O; Bonnetain F; Dahan L; Lombard-Bohas C; Faroux R; Raoul JL; Cattan S; Lemoine A; Blanc JF; Bronowicki JP; Zarski JP; Cazorla S; Gargot D; Thevenot T; Diaz E; Bastie A; Aparicio T; Bedenne L
Eur J Cancer; 2009 Jul; 45(10):1788-97. PubMed ID: 19303768
[TBL] [Abstract][Full Text] [Related]
29. Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme).
Lancet; 1998 Jul; 352(9121):17-20. PubMed ID: 9800740
[TBL] [Abstract][Full Text] [Related]
30. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
31. Biologic study of the effects of octreotide-LAR on growth hormone in unresectable and metastatic hepatocellular carcinoma.
Attia S; Holen KD; Thomas JP; Richie K; Dzelak T; Teeter K; Warren D; Bilger A; Fine J; Eickhoff J; Drinkwater N; Mulkerin D; Morgan-Meadows S
Clin Adv Hematol Oncol; 2008 Jan; 6(1):44-54. PubMed ID: 18322441
[TBL] [Abstract][Full Text] [Related]
32. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area.
Park KW; Park JW; Choi JI; Kim TH; Kim SH; Park HS; Lee WJ; Park SJ; Hong EK; Kim CM
J Gastroenterol Hepatol; 2008 Mar; 23(3):467-73. PubMed ID: 17764529
[TBL] [Abstract][Full Text] [Related]
33. Survival after adjuvant oophorectomy and tamoxifen in operable breast cancer in premenopausal women.
Love RR; Van Dinh N; Quy TT; Linh ND; Tung ND; Shen TZ; Hade EM; Young GS; Jarjoura D
J Clin Oncol; 2008 Jan; 26(2):253-7. PubMed ID: 18086800
[TBL] [Abstract][Full Text] [Related]
34. Value of the model for end-stage liver disease for predicting survival in hepatocellular carcinoma patients treated with transarterial chemoembolization.
Kim JH; Kim JH; Choi JH; Kim CH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
Scand J Gastroenterol; 2009; 44(3):346-57. PubMed ID: 18991165
[TBL] [Abstract][Full Text] [Related]
35. A new prognostic score system in patients with advanced hepatocellular carcinoma not amendable to locoregional therapy: implication for patient selection in systemic therapy trials.
Yau T; Yao TJ; Chan P; Ng K; Fan ST; Poon RT
Cancer; 2008 Nov; 113(10):2742-51. PubMed ID: 18853421
[TBL] [Abstract][Full Text] [Related]
36. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation.
Takahashi S; Kudo M; Chung H; Inoue T; Nagashima M; Kitai S; Tatsumi C; Minami Y; Ueshima K; Fukunaga T; Haji S
Dig Dis; 2007; 25(4):303-9. PubMed ID: 17960064
[TBL] [Abstract][Full Text] [Related]
37. Predictors of survival after resection of early hepatocellular carcinoma.
Nathan H; Schulick RD; Choti MA; Pawlik TM
Ann Surg; 2009 May; 249(5):799-805. PubMed ID: 19387322
[TBL] [Abstract][Full Text] [Related]
38. Serum alpha-fetoprotein response as a surrogate for clinical outcome in patients receiving systemic therapy for advanced hepatocellular carcinoma.
Vora SR; Zheng H; Stadler ZK; Fuchs CS; Zhu AX
Oncologist; 2009 Jul; 14(7):717-25. PubMed ID: 19581525
[TBL] [Abstract][Full Text] [Related]
39. Liver resection or combined chemoembolization and radiofrequency ablation improve survival in patients with hepatocellular carcinoma.
Helmberger T; Dogan S; Straub G; Schrader A; Jüngst C; Reiser M; Waggershauser T; Jakobs T; Hoffmann RT; Löhe F; Graeb C; Rau HG; Schauer R; Jauch KW; Caselmann WH; Göke B; Jüngst D
Digestion; 2007; 75(2-3):104-12. PubMed ID: 17598962
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of epirubicin and etoposide combination chemotherapy in advanced hepatocellular carcinoma: a retrospective analysis.
Lee JL; Ryu MH; Chang HM; Kim TW; Lee SS; Sym SJ; Kim MK; Kim KM; Lee JS; Kang YK
J Gastroenterol Hepatol; 2008 May; 23(5):811-6. PubMed ID: 17995941
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
